Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients

Tiago Torres, Margarida Gonçalo, Maria João Paiva Lopes, Cristina Claro, Leonor Ramos, Manuela Selores, Pedro Mendes Bastos, Joana Rocha, Rodrigo Carvalho, Alberto Mota, Paulo Filipe

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)

Abstract

Atopic dermatitis is a highly prevalent chronic, immune-mediated inflammatory skin disease with a significant burden on patients, families and healthcare systems. This article presents recommendations developed by the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology addressing several clinical questions that arise in the management and care of moderate-to-severe atopic dermatitis with biologic agents and Janus kinase (JAK) inhibitors based on the available evidence. The recommendations were generated after a thorough evaluation of existing guidelines on the treatment of atopic dermatitis, publications concerning new biologics and JAK inhibitors not yet incorporated into existing guidelines, and expert-based recommendations. It also includes considerations on atopic dermatitis severity, indications for initiating biologic agents and JAK inhibitors, parameters to be considered in the treatment choice, in particular treatment goals, and recommendations for the use, screening and monitoring of these therapies.

Original languageEnglish
Article number10
JournalDrugs in Context
Volume10
DOIs
Publication statusPublished - 2021

Keywords

  • Atopic dermatitis
  • Biologic therapy
  • Guidelines
  • JAK inhibitors
  • Recommendations
  • Treatment goals

Fingerprint

Dive into the research topics of 'Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients'. Together they form a unique fingerprint.

Cite this